Manufacturers report rapid time to clinical response for Lefamulin in community-acquired bacterial pneumonia

In a post-hoc analysis of the LEAP trials (total 926 patients), lefamulin (a pleuromutilin antibiotic under investigation) produced an identical time to clinical response and time to clinical stability as moxifloxacin (3 days for all endpoints for both treatments).

Source:

Biospace Inc.